For the analysis, researchers examined drugmakers’ Securities and Exchange Commission filings, company reports and media coverage, among other sources. They also conducted interviews with drug executives. In total, researchers identified 58 phase II drugs and 30 phase III drugs in development in 2017. The 2017 numbers mark an 18-percent increase of in-development phase II drugs and a 7 percent increase of in-development phase III drugs since 2016.
“The Alzheimer’s disease pipeline, marred by decades of failures and underinvestment, is due for big victories,” said George Vradenburg, UsAgainstAlzheimer’s co-founder and chairman. “Thanks to growing investment from industry leaders, we remain cautiously optimistic that the current crop of late-stage Alzheimer’s innovations will bring much-needed solutions to families in the near future.”
Six phase III Alzheimer’s drug trials are set to conclude before the end of the year.
More articles on supply chain:
Merck to build tech hub in Texas
5 drugmakers in the headlines
3 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
